- Home
- ILMN vs NTRS Comparison
ILMN vs NTRS Comparison
Compare ILMN & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- NTRS
- Stock Information
- Founded
- ILMN 1998
- NTRS 1889
- Country
- ILMN United States
- NTRS United States
- Employees
- ILMN N/A
- NTRS N/A
- Industry
- ILMN Medical Specialities
- NTRS Major Banks
- Sector
- ILMN Health Care
- NTRS Finance
- Exchange
- ILMN Nasdaq
- NTRS Nasdaq
- Market Cap
- ILMN 13.1B
- NTRS N/A
- IPO Year
- ILMN 2000
- NTRS N/A
- Fundamental
- Price
- ILMN $97.15
- NTRS $123.60
- Analyst Decision
- ILMN Buy
- NTRS Hold
- Analyst Count
- ILMN 17
- NTRS 12
- Target Price
- ILMN $124.35
- NTRS $113.00
- AVG Volume (30 Days)
- ILMN 2.4M
- NTRS 2.9M
- Earning Date
- ILMN 07-31-2025
- NTRS 07-23-2025
- Dividend Yield
- ILMN N/A
- NTRS 2.41%
- EPS Growth
- ILMN N/A
- NTRS 137.54
- EPS
- ILMN N/A
- NTRS 10.76
- Revenue
- ILMN $4,337,000,000.00
- NTRS $8,577,100,000.00
- Revenue This Year
- ILMN N/A
- NTRS N/A
- Revenue Next Year
- ILMN $3.15
- NTRS $3.86
- P/E Ratio
- ILMN N/A
- NTRS $11.56
- Revenue Growth
- ILMN N/A
- NTRS 28.50
- 52 Week Low
- ILMN $68.70
- NTRS $80.81
- 52 Week High
- ILMN $156.66
- NTRS $133.00
- Technical
- Relative Strength Index (RSI)
- ILMN 59.14
- NTRS 56.94
- Support Level
- ILMN $95.09
- NTRS $125.77
- Resistance Level
- ILMN $101.28
- NTRS $128.12
- Average True Range (ATR)
- ILMN 3.31
- NTRS 2.97
- MACD
- ILMN -0.27
- NTRS -0.74
- Stochastic Oscillator
- ILMN 58.10
- NTRS 35.04
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.